Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3Neoplasms 1Hepatoblastoma 1Fibrolamellar hepatocellular carcinoma 1

Interventions

Specimen Handling 427Magnetic Resonance Spectroscopy 338pembrolizumab 262Biopsy 230Carboplatin 216Cisplatin 180Cyclophosphamide 174Paclitaxel 148Nivolumab 136Gemcitabine 130Radiotherapy 125Dexamethasone 105Bevacizumab 103Radiation 97fludarabine 95Fluorouracil 93Doxorubicin 90Pemetrexed 88Docetaxel 85Rituximab 83durvalumab 82venetoclax 81Oxaliplatin 81Leucovorin 76atezolizumab 70Prednisone 66Lenalidomide 66Capecitabine 66Etoposide 64Vincristine 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Sorafenib × 30 days × Clear all
NCT05468359 2026-05-19

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
64 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT03017326 2026-05-13

PHITT

University of Birmingham

Phase 3 Active not recruiting
450 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Hepatoblastoma

NCT01840592 2026-05-06

Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡